The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3 Clinical Trials Not Allowed)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.
The purpose of this FOA is to support UG3/UH3 phased award Projects as part of the expanded Immuno-Oncology Translational Network (IOTN). The IOTN expansion will also include the following components supported by companion FOAs:
- U01 Cancer Immunoprevention Research Projects (to be supported by RFA-CA-19-014);
- U01 Cancer Immunotherapy Research Projects (to be supported by RFA-CA-19-015);
- U54 Immuno-engineering to Improve Immunotherapy (i3) Centers: (to be supported by RFA-CA-19-013).
The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor initiation and progression and evaluating new or improved immunopreventive and immunotherapeutic strategies (including combinations with standard or other therapies). Studies must be pre-clinical involving clinically-relevant models and endpoints, and have the potential for rapid translation into early-phase clinical applications.
Applicants responding to this FOA must apply for both the UG3 and UH3 phases together in a single application. Exploratory studies aimed at immune target identification and validation will be supported under UG3. Achievement of the UG3 milestones will be necessary for transition to the UH3 Implementation Phase. UH3 phase may be awarded after administrative review of the UG3 milestones. Provided these milestones are achieved, UH3 phase may continue with development and preclinical testing of specific interventions.
- Letter of Intent Due Date(s): 30 days prior to the application due date.
- Application Due Date(s): February 11, 2019
RFA-CA-19-012 Expiration Date February 12, 2019
Applicants may request up to $500,000 per year (direct costs) for both the UG3 phase and the UH3 phase.
The proposed project period for the initial development phase (UG3) must not exceed 2 years (but may be shorter).
The proposed project period for the second validation phase (UH3) must not exceed 3 years.